METHODS article

Front. Immunol., 17 December 2024

Sec. B Cell Biology

Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1505971

FB5P-seq-mAbs: monoclonal antibody production from FB5P-seq libraries for integrative single-cell analysis of B cells

  • 1. Aix Marseille Université, CNRS, INSERM, Centre d’Immunologie de Marseille-Luminy, Marseille, France

  • 2. Paris-Saclay University, Inserm, Gustave Roussy, Tumour Immunology and Anti-Cancer Immunotherapy, Villejuif, France

Abstract

Parallel analysis of phenotype, transcriptome and antigen receptor sequence in single B cells is a useful method for tracking B cell activation and maturation during immune responses. However, in most cases, the specificity and affinity of the B cell antigen receptor cannot be inferred from its sequence. Antibody cloning and expression from single B cells is then required for functional assays. Here we propose a method that integrates FACS-based 5’-end single-cell RNA sequencing (FB5P-seq) and monoclonal antibody cloning for integrative analysis of single B cells. Starting from a cell suspension, single B cells are FACS-sorted into 96-well plates for reverse transcription, cDNA barcoding and amplification. A fraction of the single-cell cDNA is used for preparing 5’-end RNA-seq libraries that are sequenced for retrieving transcriptome-wide gene expression and paired BCR sequences. The archived cDNA of selected cells of interest is used as input for cloning heavy and light chain variable regions into antibody expression plasmid vectors. The corresponding monoclonal antibodies are produced by transient transfection of a eukaryotic producing cell line and purified for functional assays. We provide detailed step-by-step instructions and describe results obtained on ovalbumin-specific murine germinal center B cells after immunization. Our method is robust, flexible, cost-effective, and applicable to different B cell types and species. We anticipate it will be useful for mapping antigen specificity and affinity of rare B cell subsets characterized by defined gene expression and/or antigen receptor sequence.

Introduction

In the immune response to pathogens and vaccines, antigen-responsive B cells undergo series of cellular and molecular maturation events that are required for long term immune protection and memory (). On the cellular side, activated B cells divide, migrate, and evolve through distinct intermediate differentiation stages that ultimately give rise to long-lived antibody-producing plasma cells and memory B cells (). On the molecular side, within each responding B cell, the genetic loci encoding B cell receptor (BCR) immunoglobulin heavy (IGH) and light (IGK/L) chains may undergo class switch recombination (CSR) () and somatic hypermutation (SHM) (), providing opportunities for improving the function and affinity of antigen-specific antibodies produced throughout the current and future immune responses (). In those parallel cellular and molecular evolution processes, every antigen-responsive B cell may generate a diverse progeny of clonally related daughter B cells expressing unique combinations of functional properties and BCR affinities. Thus, methods that enable integrative analysis of B cell phenotype, transcriptome, BCR sequence, and BCR affinity at the single-cell level, are useful tools when studying B cell immune responses ().

In the past few years, two types of single-cell RNA sequencing (scRNA-seq) techniques have been applied to B cells for integrative analysis of transcriptome and BCR sequence: plate-based scRNA-seq of B cells sorted by flow cytometry, either with full-length (Smart-seq2) (, ) or 5’-end sequencing (FB5P-seq) (); and droplet-based 10x Genomics 5’-end scRNA-seq (). Both techniques may link B cell transcriptome and BCR sequence with antigen-specificity, provided B cells are incubated with labeled antigen [fluorescent antigen for FACS-based methods (), DNA-barcoded antigen for droplet-based method ()] before analysis. However, those approaches are not suitable for B cells expressing low amounts of surface BCR (e.g. plasma cells), and preclude extensive analyses of BCR specificity, affinity and function.

Antibody cloning and production from single FACS-sorted memory B cells or plasmablasts [e.g. protocols described in ()], has been the method of choice for discovering and characterizing naturally occurring antigen-specific antibodies from infected individuals, notably in the fields of HIV () and SARS-CoV2 () research. Such methods, applied to animal models of protein vaccination or infection, have also contributed to our basic understanding of the role of BCR affinity during germinal center (GC) B cell responses (, ). However, in those studies, the cellular characteristics of B cells from which monoclonal antibodies (mAbs) are cloned can only be inferred from the expression of a few surface markers or of fluorescent reporters.

Here we describe FB5P-seq-mAbs, a method that bridges plate-based 5’-end scRNA-seq (FB5P-seq) with recombinant monoclonal antibody cloning and production (Figure 1), and illustrate its use for characterizing antigen-responding GC B cells after chicken ovalbumin (OVA) immunization in mice.

Figure 1

), recording fluorescence intensity parameters of each sorted cell by index sorting. FB5P-seq libraries from multiple 96-well plates are pooled, sequenced, and analyzed to identify B cell subsets, recover paired BCR heavy and light chain sequences, and integrate both information types. For selected cells of interest, the remaining single-cell amplified cDNA in archived 96-well PCR plates is used as starting material for PCR amplification of IgH VDJ and Igκ VJ sequences, and cloning into mouse IgG1 and Igκ expression vectors, respectively. IgG1 and Igκ expression plasmids are co-transfected into a eukaryotic cell line for production of recombinant mAb in the culture supernatant. After purification, recombinant IgG1/κ mAbs are available for functional assays and integrative analyses. Created with BioRender.com.

Materials and equipment

Antibodies

Reagent or resourceSourceIdentifier
CD138-BV711Biolegendcat.no.142519
CD19-PE-Dazzle594Biolegendcat.no. 115553
CD38-PEBiolegendcat.no. 356608
CD3-APC-Cy7Biolegendcat.no.100222
CXCR4-PerCP-eF710ThermoFisher Scientificcat.no. 46-9991-82
GL7-BV421Biolegendcat.no.144614
Gr1-APC-Cy7Biolegendcat.no.108424
Mouse Fc blockBiolegendcat.no.101320
OVA-AF 647ThermoFisher Scientificcat.no. O34784
HRP-coupled anti-mouse IgG secondary antibodyThermoFisher Scientificcat.no. A24512
Anti-ovalbumin (clone 6C8)Abcamcat.no. ab17293

Cell lines, mouse strains, bacteria

Reagent or resourceSourceIdentifier
Aicda-Cre-ERT2 x Rosa26-lox-STOP-lox-eYFPLe Gallou et al. ()
E.Coli JM109Promegacat.no. L2005
Expi293TMThermoFisher Scientificcat.no. A14527

Chemicals, peptides and recombinant proteins

Reagent or resourceSourceIdentifier
1Kb plus DNA ladderThermoFisher Scientificcat.no. 10787018
2N sulfuric acidThermoFisher Scientificcat.no. N600
2-PropanolSigma-Aldrichcat.no. 109634
Acetic acidVWRcat.no. 20104.334
AgaroseLife Technologiescat.no. 16500500
AgeI-HFNew England Biolabscat.no. R3552S
Alkaline PhosphataseNew England Biolabscat.no. M0525S
AlumThermoFisher Scientificcat.no. 77161
AmpicillinSigma-Aldrichcat.no. A9518
Arachidic acid oilSigma-Aldrichcat.no. A3631
BetaineSigma-Aldrichcat.no. B0300
Boric AcidCarlo Erbacat.no. 600641
Bromophenol BlueSigma-AldrichCat no. B0126-25G
Bovine Serum AlbuminSigma-Aldrichcat.no. 10735078001
BsiwINew England Biolabscat.no. R0553L
Clean NGS beadsProteigenecat.no. CNGS-0050
CutSmart BufferNew England Biolabscat.no. B7203S
Dimethyl sulfoxideMerckcat.no. 276855-100ML
dNTPThermoFisher Scientificcat.no. 10297018
EDTAThermoFisher Scientificcat.no. 15575020
EthanolSigma-Aldrichcat.no. M3148-100ML
Ethidium bromideMerckcas.no. E1510
Expi293™ mediumThermoFisher Scientificcat.no. A1435101
Fetal Calf SerumGibcocat.no. 10270-106
GlucoseMerckcat.no. 49159-1KG
GlycineThermoFisher Scientificcat no. 15527-013
GoTaq G2 Flexi enzymePromegacat no. M7801
HClDutschercat no. 524526
KAPA HiFi ReadyMixRoche Diagnosticscat.no. 7958935001
LB AgarThermoFisher Scientificcat.no. 22700025
LB mediumThermoFisher Scientificcat.no. 12780052
Live/DeadThermoFisher Scientificcat.no. L34957
Protein ladderBioradcat.no. 1610373
MethanolDutschercat.no. 412383
MgCl2Sigma-Aldrichcat.no. M1028
NaClSigma-Aldrichcat.no. S6546-1L
NEBuffer 2New England Biolabscat.no. B7202
NEBuffer 3.1New England Biolabscat.no. B7203S
Nupage novex 4-12% BT midi gelThermoFisher Scientificcat.no. WG1401BOX
NuPAGE™ MOPS SDS Running Buffer (20X)Life Technologiescat.no. NP0001
OVA antigenInvivoGencat.no. vac-stova
OVA stockThermoFisher Scientificcat.no. 77120
PBS 10 XLife Technologiescat.no. 14200067
PCR-grade H2OQiagencat.no. 129114
Penicillin-streptomycinThermoFisher Scientificcat.no. 15140122
Polyethylene glycol 3350Merckcat.no. P4338-500G
PolyethyleneimineSigma-Aldrichcat.no. 408727-100ML
Protein G beadsSigma-Aldrichcat.no. GE17-0618-01
Rnase OUTThermoFisher Scientificcat.no. 10777019
Laemmli SDS-Sample Buffer 4X, Non-ReducingClinisciencecat.no. 10570018-1
Sample Buffer Laemmli 2x ConcentrateSigma-Aldrichcat.no. S3401-10VL
SOC mediumInvitrogencat.no. 15544-034
Sodium azideMerckcat.no. S2002-5G
SuperScript IIThermoFisher Scientificcat.no. 18064014
T4 DNA polymeraseNew England Biolabscat.no. M0203S
TamoxifenSigma-Aldrichcat.no. T5648-1G
TMB SolutionThermoFisher Scientificcat.no. 34021
Tris baseLife Technologiescat.no. 15504020
Triton X-100Merckcat.no. 93443-100ML
Trypan blueMerckcat.no. T8154-20ML
TryptoneMerckcas.no. T7293-250G
Tween 20Merckcat.no. P9416-100ML
Valproic acidMerckcat.no. V0033000
XhoINew England Biolabscat.no. R0146L
Yeast extractMerckcat.no. Y1625-250G

Oligonucleotides

Reagent or resourceSourceIdentifier
(dT)30_SmarterIDTAttaf et al. ()
ERCC spike-in MixThermoFisher Scientificcat.no. 4456740
i5 primer S5xxIlluminacat.no. FC-131-2001
i7 primers mixIDTAttaf et al. ()
i7_BCx primerIDTAttaf et al. ()
Multiplex Forward PrimersIDTSupplementary Table 1
Multiplex Reverse PrimersIDTSupplementary Table 1
PCR_SatijaIDTAttaf et al. ()
Screening Forward Primers IDTSupplementary Table 2
Screening Reverse Primers IDTSupplementary Table 2
SmarterR IDTAttaf et al. ()
TSO_BCx_UMI5_TATAIDTAttaf et al. ()

Commercial assays

Reagent or resourceSourceIdentifier
High Sensitivity DNA chip analysisAgilentcat.no. 5067-4626
High Speed Midi KitQiagencat.no. 12643
Nextera XT DNA sample Preparation kitIlluminacat.no. FC-131-1096
QIAquick 96 PCR Purification KitQiagencat.no. 28181
QIAquick Gel Extraction KitQiagencat.no. 28704
Qubit HS DNA testThermoFisher Scientificcat.no. Q32854

Equipment

Reagent or resourceSourceIdentifier
8-channel micropipette 10 µlStarlabcat.no. S7108-0510
8-channel micropipette 100 µlStarlabcat.no. S7108-1100
8-channel micropipette 300 µlStarlabcat.no. S7108-3300
BD Influx™ Cell SorterBD BiosciencesNA
Benchtop plate centrifugeStarlabcat.no. N2631-0008
IncubatorFisher Scientificcat.no. 12815883
DynaMag™-96ThermoFisher Scientificcat.no. 12331D
NanodropThermoFisher Scientificcat.no. ND-ONE
p10 micropipetteStarlabcat.no. S7100-0510
p1000 micropipetteStarlabcat.no. S7110-1000
p200 micropipetteStarlabcat.no. S7100-2200
Plate readerBMG LABTECHNA
ShakerVWRcat.no. 444-4227
SonicatorKinematicacat.no. HS1200 E
Thermal CyclerThermoFisher Scientificcat.no. A24811
UV lightDutschercat.no. 5207326
VortexDutschercat.no. 79008

Consumables

Reagent or resourceSourceIdentifier
0.22-micron steritop filtersMilliporecat.no. SCGPT01RE
0.3 ml syringeDutschercat.no. 324826
1.5 ml tubeEppendorfcat.no. 30108051
10 ml serological pipetteBecton dickinsoncat.no. 357551
10 μl filter tipsStarlabcat.no. S1120-3810
1000 μl filter tipsDutschercat.no. 134000CL
15 ml tubeDutschercat.no. 352096
200 μl filter tipsSarstedtcat.no. 3070279
25 ml serological pipetteSarstedtcat.no. 86.1685.001
30 KD amiconMerckcat.no. UFC503024
5 ml FACS tubesDutschercat.no. 352054
5 ml serological pipetteSarstedtcat.no. 86.1253.001
50 ml tubeSarstedtcat.no. 62.547.254
70 µm cell strainerSarstedtcat.no. 83.3945.070
8-tube PCR stripMerckcat.no. EP0030124359
96 round bottomDutschercat.no. 353077
96-well ELISA platesThermoFisher Scientificcat.no. 467320
96-well PCR platesThermoFisher Scientificcat.no. 4483485
Adhesive filmLife Technologiescat.no. 4306311
Aluminum foilVWRcat.no. 291-0045
Chromatography columnsSigmacat.no. 7311550
Dissection scissorsDutschercat.no. HWB 002-11
Flasks with vented capsDutschercat.no. 355121B
Gavage syringeFine Science Toolscat.no. 18061-22
MicroAmp EnduraPlate Optical 96-Well platesThermoFisher Scientificcat.no. 4483485
ParafilmMerckcat.no. 291-1213
PCR tubeEppendorfcat.no. 30124359
Petri DishDutschercat.no. 633180
Pre-Separation FilterMiltenyi Bioteccat.no. 130-041-407
Reservoir for multichannel pipettesSigmacat.no. 4870
StericupMilliporecat.no. S2GPU05RE
Tube DNA LoBind 0.5 mlMerckcat.no. EP0030108035
Tube DNA LoBind 1.5 mlMerckcat.no. EP0030108051

Software

Reagent or resourceSourceIdentifier
Adobe Illustrator CC 2019Adobehttps://www.adobe.com/fr/products/illustrator.html
BlastnNCBIhttps://blast.ncbi.nlm.nih.gov/
BD FACS sortBD BiosciencesNot Available
FlowJo v10.8BD Bioscienceshttps://www.flowjo.com/
ggplot2Not Applicablehttps://ggplot2.tidyverse.org/
GraphPad Prism 9GraphPad Softwarehttps://graphpad.com/scientific-software/prism/
IgBlastNCBIhttps://www.ncbi.nlm.nih.gov/igblast/
SnapGeneSnapGenehttps://www.snapgene.com
MS Excel 2016Microsofthttps://www.microsoft.com/fr
Adobe Photoshop CC 2019Adobehttps://www.adobe.com/fr/products/photoshop/landpb.html
FB5P-seqNot Applicablehttps://github.com/MilpiedLab/FB5P-seq
Seurat v4Not Applicablehttps://satijalab.org/seurat/

Methods

Mouse model

Aicda-Cre-ERT2 x Rosa26-lox-STOP-lox-eYFP mice () were bred at the Centre d’Immuno-Phenomique, (Marseille, France), and transferred to the animal care facility of Centre d’Immunologie de Marseille-Luminy for experiments. All mice were maintained in the CIML mouse facility under specific pathogen-free conditions. Experimental procedures were conducted in agreement with French and European guidelines for animal care under the authorization number APAFIS #30945-2021040807508680, following review and approval by the local animal ethics committee in Marseille. Mice were used regardless of sex, at ages greater than 7 weeks and less than 3 months.

Mice were immunized with 100µg chicken ovalbumin (OVA) at 1µg/µl emulsified with Alum at a 1:1 (v:v) ratio, subcutaneously at the base of the tail, 50µl on each side. For induction of the Cre-ERT2-mediated labelling, we gavaged the mice once with 5mg of tamoxifen (TS648-1G, Sigma) in 200µL of peanut oil (P2144-250 ML, Sigma), at least 6 days after immunization. Mice were euthanized between 10 days and 21 days post-immunization (prime or boost) according to the experiment (Figure 2B).

Figure 2

Flow cytometry and cell sorting of B cell subsets

Single-cell suspensions from draining lymph nodes were washed and resuspended in FACS buffer (5% fetal calf serum, 2mM EDTA, 5% Brilliant Stain Buffer Plus in PBS 1X) at a concentration of 100 million of cells per ml. For each dLN cell suspension, we stained 5 million cells in a final volume of 100 µl (50 µl of cells at a 100 x 106 cells/ml concentration, plus 50 µl of antibody mix). We used single-color compensation controls to verify the settings of the cytometer on the day of the sort, running the experiment on a template that had been previously established according to good cytometry practice. Cells were first incubated with FcBlock (Biolegend) for 10 min on ice. Then, cells were incubated with a mix of antibodies conjugated with fluorochromes 30 min on ice. Cells were washed in PBS, and incubated with the Live/Dead Fixable Aqua Dead Cell Stain (Thermofisher) for 10 min on ice. Cells were then washed again in FACS buffer and resuspended in FACS buffer. Cells were sorted on the BD Influx™ Cell Sorter, in 96-well plates, with index-sorting mode for recording the fluorescence parameters associated to each sorted cell.

FB5P-seq library preparation, sequencing and data pre-processing

The protocol was performed as previously described by Attaf et al. (). Individual cells were sorted into a 96-well PCR plate, with each well containing 2 µL of lysis buffer. Index sort mode was activated to record the fluorescence intensities of all markers for each individual cell. Flow cytometry standard (FCS) files from the index sort were analyzed using FlowJo software, and compensated parameters were exported as CSV tables for subsequent bioinformatic analysis. Immediately after sorting, plates containing individual cells were stored at -80°C until further processing. Following thawing, reverse transcription was performed, and the resulting cDNA was preamplified for 22 cycles. Libraries were then prepared according to the FB5P-seq protocol. The FB5P-seq data were processed to generate both a single-cell gene count matrix and single-cell B cell receptor (BCR) repertoire sequences for B cell analysis. Two separate bioinformatic pipelines were employed for gene expression and repertoire analysis, as detailed in Attaf et al. ().

Bioinformatics analysis

We used a custom bioinformatics pipeline to process fastq files and generate single-cell gene expression matrices and BCR sequence files as previously described (). Detailed instructions for running the FB5P-seq bioinformatics pipeline can be found at https://github.com/MilpiedLab/FB5P-seq. Quality control was performed on each dataset independently to remove poor quality cells based on UMI counts, number of genes detected, ERCC spike-in quantification accuracy, and percentage of transcripts from mitochondrial genes. For each cell, gene expression UMI count values were log-normalized with Seurat NormalizeData with a scale factor of 10,000 to generate normalized UMI count matrices.

Index-sorting FCS files were visualized in FlowJo software and compensated parameters values were exported in CSV tables for further processing. For visualization on linear scales in the R programming software, we applied the hyperbolic arcsine transformation on fluorescence parameters ().

For BCR sequence reconstruction, the outputs of the FB5P-seq pipeline were further processed and filtered with custom R scripts. For each cell, reconstructed contigs corresponding to the same V(D)J rearrangement were merged, keeping the largest sequence for further analysis. We discarded contigs with no constant region identified in-frame with the V(D)J rearrangement. In cases where several contigs corresponding to the same BCR chain had passed the above filters, we retained the contig with the highest expression level. BCR metadata from the MigMap and Blastn annotations were appended to the gene expression and index sorting metadata for each cell.

Supervised annotation of scRNA-seq datasets were performed as described extensively in Figure 2B and Supplementary Figure 2C of Binet et al. (). Briefly, we used the AddModuleScore function to compute gene expression scores for every cell in the dataset for the cell type specific signatures. For DZ and LZ signatures, genes associated to cell cycle ontologies (based on GO terms), were removed from the gene lists prior to scoring, as described in Milpied et al. (). Thresholds for “gating” were defined empirically. Single-cell gene expression heatmaps were generated by the doheatmap function in R.

BCR amplification and cloning

From the FACS-sorted single-cell RNA-seq libraries in 96-well PCR plates, 2 µl of each well of the plate was diluted. This diluted cDNA was used to amplify the variable regions with a multiplex PCR (Supplementary Table 1). After verification of the amplification on an agarose gel, the PCR products were purified and adjusted to the concentration necessary to perform the cloning (40 ng/µl). Cloning of the variable regions was done by SLIC (Sequence and ligation-independent cloning) in 1 µl of each linearized and pre-purified expression vector concentrated at 40 ng/µl (). To verify that the inserts had been cloned into each expression vector, the colonies were screened by PCR and a bacterial colony fingerprint was made. The primers used were specific to each IgH and IgK vector (Supplementary Table 2). The two vectors used in this study were kindly provided by the Nussenzweig laboratory ().

Plasmid DNA preparations were made from the screened positive bacterial fingerprints and each construct was sequenced and checked against the original sequences.

Antibody production

The Expi293™ cells grown in Expi293™ Expression Medium were cultured in sterile vented-cap Erlenmeyer flasks. On the day of transfection, the heavy chain-containing vectors and light chain-containing vectors were incubated in the presence of polyethyleneimine. The cells were incubated for 6 days in the incubator. The culture supernatants were then centrifuged, filtered and the antibodies present in supernatant were purified on protein G beads on polyprep chromatography columns.

Antibody analysis by ELISA

OVA antigen at 20 µg/ml was coated in 96-well ELISA plates (50 µl per well) for incubation overnight at 4°C. After 3 washes with PBS + Tween 0.05%, the plate was blocked with 100 μl of blocking buffer (PBS + 2% BSA) and incubated for 2h at room temperature. After 3 washes, a stepwise serial dilution (dilution factor 4), starting from 1 µg antibody per well was prepared for control and target antibodies, and was added to the plate wells in two replicates (50 µl per well) and incubated for 2h at room temperature. In all assays, we included a commercial anti-OVA monoclonal antibody (clone 6C8) as a positive control, and no primary antibody (only secondary HRP-conjugated anti-IgG antibody) as a negative control. After 3 washes, HRP-coupled anti-mouse IgG secondary antibody diluted 4000-fold was added and incubated for 2h at room temperature. After 3 washes, 100 µl of TMB solution was added and incubated for 15 min. The reaction was stopped by adding 100 µl of 2N sulfuric acid. The reaction was measured with a plate reader at 450 nm.

Detailed protocol

A detailed reagent setup protocol is presented in Supplementary Table 3.

A detailed step-by-step protocol is presented in Supplementary Table 4.

Limitations

The amplification of the Ig genes may be dependent on the sequence of the V genes sequences of the isolated B cells. It may be necessary to amplify the BCR from a larger number of cells to obtain the sufficient number of Ig. However, the knowledge of each BCR sequence upstream of the amplification, can be a precious help in the failure of some V gene PCR products, by being able to specifically adapt the sequence of the primers.

The cloning of variable chains by the SLIC method can be variable. This can be due to the purification of the PCR products or the efficiency of the reaction. In this case, it is possible to overcome this problem by a classical cloning technique which is made possible by the presence of restriction enzyme sites in the PCR products of each chain.

The Elisa control experiment which is performed the day before antibody purification is a good indication of antibody production in the culture supernatant. However, the level of production does not always reflect the total amount of antibodies obtained after purification. This depends on the ability of the antibodies to bind to the protein-G beads due to their structure or purity.

Troubleshooting

A detailed troubleshooting table is presented as Supplementary Table 5.

Results

We applied FB5P-seq-mAbs to study murine GC B cells after prime or prime-boost immunization with the model antigen chicken ovalbumin (OVA). We used the Aicda-Cre-ERT2+/- x Rosa26-eYFP-lox-stop-lox+/- mouse model (, ) for fate mapping GC B cells and their progeny after tamoxifen gavage of immunized mice (Figure 2A). Mice were immunized with OVA and alum adjuvant subcutaneously, once for prime immunizations, a second time 11 weeks later for prime-boost immunizations, and gavaged with tamoxifen 4 days before sacrifice and collection of draining lymph nodes; draining lymph nodes were collected 10 or 20 days after primary (d10p, d20p), or after secondary (d10s, d20s) immunization (Figure 2B). GC B cells and their progeny were gated as live IgD-negative B cells expressing eYFP, and were further subdivided as CD138+ plasma cells (PC), CD19+GL7+CD38- GC B cells, or CD19+CD38+GL7- memory B cells (Mem) (Figure 2C). As expected, eYFP+ GC B cells outnumbered their Mem and PC progeny at days 10 or 20 after primary or secondary immunization in draining lymph nodes (Figure 2D). Among IgDneg eYFP+ B cells, OVA-binding cells were a minority, representing an average of 20-30% (Figure 2E).

We sorted single IgDneg eYFP+ B cells from d10p, d20p, d10s and d20s draining lymph nodes, in order to gain access to GC B cells with distinct levels of affinity maturation and somatic hypermutation, and prepared 5’-end scRNA-seq libraries with the FB5P-seq protocol (). All surface staining parameters, including binding of OVA-AlexaFluor647 (OVA-AF647) antigen, were recorded by index sorting and appended to the gene-by-cell UMI count matrix. We also used the FB5P-seq bioinformatic pipeline to reconstruct the Igh and Igk/l variable region sequences from 5’-end scRNA-seq reads (9). After quality controls, we retained 769 cells(d10p: 145 cells; d20p: 205 cells; d10s: 295 cells; d20s: 124 cells), including 573 cells with paired full Igh and Igk/l variable region sequences (d10p: 101 cells; d20p: 158 cells; d10s: 218 cells; d20s: 91 cells). Based on signature gene expression, we annotated the majority of cells as LZ (n=331), DZ (n=300) or recycling LZtoDZ (n=55) GC B cells, and identified minor fractions of putative preMem (n=29), prePC (n=27), or bona fide PC (n=5) (Figure 3A). Consistent with other scRNA-seq studies of murine GC B cells (), LZ cells expressed high levels of Fcer2a (encoding CD23), Cd83, H2-Oa (encoding MHC-II subunit), Cd86 and Nfkbia transcripts and were mostly quiescent or in S phase. DZ cells expressed high levels of Gcsam, Ccnb2, Hmces, Pafah1b3 and Stmn1 transcripts, and were mostly in G2/M phase. LZtoDZ cells expressed both LZ and DZ marker genes, as well as high levels of C1qbp, Pa2g4, Apex1, Nop58 and Exosc7 transcripts, and were mostly in S phase. PreMem cells expressed LZ marker genes, as well as high levels of Serpinb1a, Capg, Ms4a4c, Gpr183 and Btg1 transcripts, and were quiescent. PrePC cells were transcriptionally close to LZtoDZ cells, with additional expression of Sub1, Pdia4, Emb, Glo1, Polr2h transcripts, and were mostly proliferating. PC expressed high levels of some PrePC marker genes (Sub1, Pdia4) and other transcripts associated with antibody-producing cells differentiation such as Sdc1 (encoding CD138), Fam46c, Irf4, Bst2, and Glipr1.

Figure 3

Consistent with ongoing affinity maturation occurring in primary and secondary GC, the number of Ighv mutations increased from d10p to d20p, and then further increased from d10s to d20s (Figure 3B). Surface binding of OVA-AF647 antigen, a flow cytometry-based measurement of BCR affinity for the immunizing OVA antigen, was not correlated to the number of Ighv total or non-silent mutations (Figure 3C). Among the different cell subsets, recycling LZtoDZ cells had the highest rate of OVA-AF647 binding (Figure 3D), consistent with high affinity antigen-specific cells being selected and recycled from LZ GC B cells at all stages of primary and secondary GC reactions. We used Ighv sequence information to identify groups of clonally related cells (clonotypes). We retrieved 291 distinct clonotypes, including 188 unique clones and 103 clonotypes with two or more cells. We randomly selected 5 clonotypes among clonotypes of size ≥5 containing at least 1 cell with OVA-AF647 surface binding above background (Figure 3E) for recombinant mAb expression. Those clonotypes were from d10p (c127, c184, c248) and d10s (c87, c179) animals.

For each of those selected clonotypes, we designed unmutated germline sequences for the Ighv and Igkv chains, and had them synthesized with appropriate 5’ and 3’ ends for direct cloning into our IgG1 and IgK expression vectors. All other Ighv and Igkv sequences were amplified and cloned directly from the archived single-cell cDNA obtained in the FB5P-seq protocol, as detailed in the methods. We succeeded to obtain significant amounts of recombinant mAb for 5/5 cells for clonotype c179, 5/5 cells for clonotype c248, 7/8 cells for clonotype c127, 7/8 cells for clonotype c87, and 8/10 cells for clonotype c184. Failures were due to unsuccessful PCR for one of the two chains of a given cell. In some cases where the multiplexed PCR failed, we used the reconstructed Ighv sequence from the FB5P-seq pipeline to design sequence-specific forward primers for Ighv amplification, and obtained PCR products that were cloned and used to produce mAbs.

We then tested serial dilutions of those mAbs for OVA binding in indirect ELISA assays (Figures 4A–E). For all clonotypes, at least one mAb detectably bound OVA, albeit at very high concentration for clonotype c248 (Figure 4B). As expected, there was intraclonal heterogeneity in antigen binding capacity of single-cell mAbs, with most mAbs binding better than the germline for all clonotypes except c127 (Figures 4A–E), but some mAbs having no detectable OVA binding for clonotypes c179 (Figure 4A), c248 (Figure 4B), c87 (Figure 4D) and c184 (Figure 4E). For clonotype c127, none of the GC B cell-derived mAbs bound better than the germline (Figure 4C). Based on the ELISA binding curves, we computed the ELISA Binding Threshold values for all mAbs, reflecting the minimum amount of mAbs giving detectable binding in our ELISA assays. There was no association between the number of mutations in the Ighv or Igkv regions and the ELISA Binding Threshold (Table 1), but there was a significant correlation between the ELISA Binding Threshold and the OVA-AF647 surface binding measured by index sorting (Table 1, Figure 5A), even for intraclonal comparisons. Most cells which had surface binding of OVA-AF647 above 1, corresponding to signal above background noise, produced mAbs with ELISA Binding Threshold below 10 ng. Conversely, most cells which had surface binding of OVA-AF647 below 1 produced mAbs with ELISA Binding Threshold above 100 ng. Thus, OVA-AF647 surface binding is a good proxy for assessing antigen-binding properties of the BCR in single GC B cells. Nevertheless, 5 outlier cells, 3 of which were from clonotype c184, had no detectable surface binding of OVA-AF647, but produced mAbs with ELISA Binding Threshold values between 10 and 100 ng, suggesting that the FACS assay may be less sensitive than the ELISA on recombinant mAbs. We inspected the expression of subset-specific marker genes in individual cells in relation with the binding capacities of their BCR measured by FACS and ELISA (Figure 5B). Consistent with our observations on the total dataset (Figure 3D), it was interesting to note that for clonotypes c179, c87 and c127, most of the cells with good OVA-binding capacity expressed genes associated with LZ, DZ, and LZtoDZ states. For both clonotypes c127 and c184, we captured one cell in PreMem state that expressed OVA-binding BCR with ELISA Binding Threshold values in the 10 ng range, consistent with the selection of Mem B cells from mid-affinity GC B cells ().

Table 1

number of mutationsELISA binding threshold (ng)OVA-AF647 binding (asinh(MFI/100))
VHVK
CDRFWCDRFW
c179 (IGHV1-42*01_IGKV4-80*01)
germline0000>1000Not Available
p7.BC76101019.032.14
p7.BC410121>10000.06
p7.BC4901000.271.86
p8.BC7510104.851.53
p8.BC4600003.861.46
c248 (IGHV1-26*01_IGKV4-61*01)
germline0000>1000Not Available
p9.BC452300>10000.03
p9.BC76210014.940.04
p9.BC372100615.180.44
p9.BC6101005390.21
p9.BC6400004120.60
c127 (IGHV1-64*01_IGKV1-99*01)
germline00000.75Not Available
p9.BC1611022191.35
p9.BC7810005020.27
p9.BC4111011.741.89
p10.BC300001.61.57
p9.BC110001290.68
p9.BC1800003.21.27
p10.BC5011008.92.06
c87 (IGHV1-63*01_IGKV1-117*01)
germline0000>1000Not Available
p8.BC5025230.81.93
p7.BC3121013360.48
p7.BC19120210.80.24
p7.BC1613101.941.43
p8.BC8321111.731.41
p7.BC100100.741.64
p7.BC2700000.421.09
c184 (IGHV1-81*01_IGKV13-84*01)
germline0000>1000Not Available
p10.BC30110414.60.13
p9.BC62022>10000.03
p10.BC5700003521.47
p9.BC7511004510.05
p10.BC74100424.80.33
p10.BC3811002800.94
p9.BC251200>10000.00
p9.BC402000170.31

Characteristics of recombinant mAbs produced from OVA-specific GC B cell clonotypes.

For all mAbs grouped by clonotype, the number of mutations in the CDR or framework (FW) regions of the heavy (VH) and light (VK) chains are indicated in the first 4 columns, the ELISA Binding Threshold in ng in the 5th column, and the OVA-AF647 surface binding measured by index sorting in the 6th column.

Figure 4

Figure 5

Altogether, those results illustrate some of the quantitative single-cell analyses that are made possible when integrating phenotypic, transcriptomic, molecular and biochemical readouts on single B cells with FB5P-seq-mAbs.

Discussion

FB5P-seq-mAbs was designed as an extension of our plate-based 5’-end scRNA-seq method, FB5P-seq (). As such, it can be performed on archived single-cell cDNA months to years after preparation of the initial FB5P-seq libraries. Here, we demonstrated FB5P-seq-mAbs on mouse OVA-specific GC B cells, but it could also be applied to other antigen-specific B cell types. For example, we recently applied FB5P-seq to characterize memory B cells in mouse lungs after influenza virus infection and discovered bystander Mem B cells with no apparent specificity to influenza virus antigens (). In that case, FB5P-seq-mAbs may be useful to produce recombinant mAbs from bystander Mem B cells and screen those mAbs for other (auto)antigen specificities.

The FB5P-seq-mAbs protocol can be easily adapted to study human B cells by using the IGH and IGK/L amplification and cloning strategies described by others previously (). In FB5P-seq-mAbs, the scRNA-seq and BCR sequence reconstruction are performed before cloning of IGH and IGK/L, giving the opportunity to select only the single-cell cDNAs from specific cell states and/or clonotypes as starting material for mAb production. Knowing the IGH and IGK/L sequences before cloning is also particularly interesting when working with highly mutated B cells, because it allows the design of cell-specific or clonotype-specific PCR primers instead of multiplexed PCR primers that may not be optimal.

FB5P-seq-mAbs is modular, and equivalent integrative single-cell analyses of B cells may be obtained via distinct alternatives. Other plate-based single-cell RNA-seq library preparation protocols, such as Smart-seq2 () or Smart-seq3 (30), may be used to produce single-cell gene expression and BCR sequencing data and archive single-cell cDNA for recombinant mAb production. Other cloning and expression methods may be used to produce recombinant mAbs from single-cell cDNA (31). Another possibility is to use high-throughput droplet-based methods for characterization of phenotype, gene expression, BCR sequence and antigen binding (), then select cells of interest in silico and have their IGH and IGK/L V genes synthesized for direct cloning and production.

The two main directions for improving FB5P-seq-mAbs are depth and throughput. First, we may modify the FB5P-seq protocol to adopt recent improvements to plate-based scRNA-seq protocols that make them more sensitive and easier to perform. For example, we may implement the one-step RT-PCR of the recently published FLASH-seq-UMI protocol (32) which resulted in higher sensitivity and shorter library preparation time when compared to the Smart-seq3 approach. Second, we may implement antibody cloning and production strategies that are designed for higher throughput (33, 34) and can be automatized.

FB5P-seq-mAbs and its future improved versions will be important to continue the in-depth studies of antigen-specific B cell responses in animal models, and to discover the antigen reactivity and affinity of B cells in human infectious diseases, autoimmunity and cancer.

Statements

Data availability statement

Publicly available datasets were analyzed in this study. This data can be found here: NCBI GEO accession number GSE275121.

Ethics statement

The animal study and experimental procedures were conducted in agreement with French and European guidelines for animal care under the authorization number APAFIS #30945-2021040807508680, following review and approval by the local animal ethics committee in Marseille. The study was conducted in accordance with the local legislation and institutional requirements.

Author contributions

SA: Investigation, Methodology, Writing – original draft, Writing – review & editing. CD: Formal analysis, Methodology, Writing – review & editing. NA: Investigation, Methodology, Writing – review & editing. MM: Investigation, Methodology, Writing – review & editing. AC: Investigation, Writing – review & editing. PM: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing. J-MN: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants from ANR (ANR-17-CE15-0009-01 JCJC MoDEx-GC) and Inserm ITMO Cancer (grant number ASC19008ASA) to PM. This work was supported by institutional grants from INSERM, CNRS, and Aix-Marseille University to the CIML. NA was supported by fellowships from the French Ministry of Research and Higher Education.

Acknowledgments

We thank all members of the Integrative B cell Immunology lab of CIML for useful comments and discussions. We thank the Animal Care, Flow Cytometry, Genomics, and Computational Biology, Bioinformatics and Modeling core facilities of CIML for support in our experiments and analyses. We thank Dr Lotta von Boehmer and Anna Gazumyan from Pr Michel Nussenzweig’s lab for sending us antibody production vectors and providing useful tips for antibody production. We thank Dr Benjamin Rossi from Innate Pharma for providing useful tips for antibody production. Centre de Calcul Intensif d’Aix-Marseille is acknowledged for granting access to its high-performance computing resources.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2024.1505971/full#supplementary-material

References

  • 1

    McHeyzer-WilliamsMOkitsuSWangNMcHeyzer-WilliamsL. Molecular programming of B cell memory. Nat Rev Immunol. (2012) 12:2434. doi: 10.1038/nri3128

  • 2

    CysterJGAllenCDC. B cell responses: cell interaction dynamics and decisions. Cell. (2019) 177:524–40. doi: 10.1016/j.cell.2019.03.016

  • 3

    StavnezerJGuikemaJEJSchraderCE. Mechanism and regulation of class switch recombination. Annu Rev Immunol. (2008) 26:261–92. doi: 10.1146/annurev.immunol.26.021607.090248

  • 4

    PeledJUKuangFLIglesias-UsselMDRoaSKalisSLGoodmanMFet al. The biochemistry of somatic hypermutation. Annu Rev Immunol. (2008) 26:481511. doi: 10.1146/annurev.immunol.26.021607.090236

  • 5

    VictoraGDNussenzweigMC. Germinal centers. Annu Rev Immunol. (2012) 30:429–57. doi: 10.1146/annurev-immunol-020711-075032

  • 6

    AttafNBaakliniSBinetLMilpiedP. Heterogeneity of germinal center B cells: New insights from single-cell studies. Eur J Immunol. 51(11):2555–67. doi: 10.1002/eji.202149235

  • 7

    PicelliSBjörklundÅKFaridaniORSagasserSWinbergGSandbergR. Smart-seq2 for sensitive full-length transcriptome profiling in single cells. Nat Methods. (2013) 10:1096–8. doi: 10.1038/nmeth.2639

  • 8

    LindemanIEmertonGMamanovaLSnirOPolanskiKQiaoS-Wet al. BraCeR: B-cell-receptor reconstruction and clonality inference from single-cell RNA-seq. Nat Methods. (2018) 15:563–5. doi: 10.1038/s41592-018-0082-3

  • 9

    AttafNCervera-MarzalIDongCGilLRenandASpinelliLet al. FB5P-seq: FACS-based 5-prime end single-cell RNA-seq for integrative analysis of transcriptome and antigen receptor repertoire in B and T cells. Front Immunol. (2020) 11:216. doi: 10.3389/fimmu.2020.00216

  • 10

    MimitouEPChengAMontalbanoAHaoSStoeckiusMLegutMet al. Expanding the CITE-seq tool-kit: Detection of proteins, transcriptomes, clonotypes and CRISPR perturbations with multiplexing, in a single assay. Nat Methods. (2019) 16:409–12. doi: 10.1038/s41592-019-0392-0

  • 11

    GregoireCSpinelliLVillazala-MerinoSGilLHolgadoMPMoussaMet al. Viral infection engenders bona fide and bystander subsets of lung-resident memory B cells through a permissive mechanism. Immunity. (2022) 55(7):1216–33. doi: 10.1016/j.immuni.2022.06.002

  • 12

    SetliffIShiakolasARPilewskiKAMurjiAAMapengoREJanowskaKet al. High-throughput mapping of B cell receptor sequences to antigen specificity. Cell. (2019) 179:16361646.e15. doi: 10.1016/j.cell.2019.11.003

  • 13

    TillerTMeffreEYurasovSTsuijiMNussenzweigMCWardemannH. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods. (2008) 329:112–24. doi: 10.1016/j.jim.2007.09.017

  • 14

    TillerTBusseCEWardemannH. Cloning and expression of murine Ig genes from single B cells. J Immunol Methods. (2009) 350:183–93. doi: 10.1016/j.jim.2009.08.009

  • 15

    von BoehmerLLiuCAckermanSGitlinADWangQGazumyanAet al. Sequencing and cloning of antigen-specific antibodies from mouse memory B cells. Nat Protoc. (2016) 11:1908–23. doi: 10.1038/nprot.2016.102

  • 16

    KleinFMouquetHDosenovicPScheidJScharfLNussenzweigMC. Antibodies in HIV-1 vaccine development and therapy. Science. (2013) 341:1199–204. doi: 10.1126/science.1241144

  • 17

    VanshyllaKFanCWunschMPoopalasingamNMeijersMKreerCet al. Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. Cell Host Microbe. (2022) 30:6982.e10. doi: 10.1016/j.chom.2021.12.010

  • 18

    ViantCWeymarGHJEscolanoAChenSHartwegerHCipollaMet al. Antibody affinity shapes the choice between memory and germinal center B cell fates. Cell. (2020) 83(5):1298–311. doi: 10.1016/j.cell.2020.09.063

  • 19

    MayerCTGazumyanAKaraEEGitlinADGolijaninJViantCet al. The microanatomic segregation of selection by apoptosis in the germinal center. Science. (2017) 117(40):24957–63. doi: 10.1126/science.aao2602

  • 20

    Le GallouSNojimaTKitamuraDWeillJ-CReynaudC-A. The AID-cre-ERT2 model: A tool for monitoring B cell immune responses and generating selective hybridomas. Methods Mol Biol. (2017) 1623:243–51. doi: 10.1007/978-1-4939-7095-7_19

  • 21

    FinakGPerezJ-MWengAGottardoR. Optimizing transformations for automated, high throughput analysis of flow cytometry data. BMC Bioinf. (2010) 11:546. doi: 10.1186/1471-2105-11-546

  • 22

    BinetLDongCAttafNGilLFalletMBoudierTet al. Specific pre-plasma cell states and local proliferation at the dark zone – medulla interface characterize germinal center-derived plasma cell differentiation in lymph node. (2024). doi: 10.1101/2024.07.26.605240. 2024.07.26.605240.

  • 23

    MilpiedPCervera-MarzalIMollichellaM-LTessonBBrisouGTraverse-GlehenAet al. Human germinal center transcriptional programs are de-synchronized in B cell lymphoma. Nat Immunol. (2018) 19:1013–24. doi: 10.1038/s41590-018-0181-4

  • 24

    JeongJ-YYimH-SRyuJ-YLeeHSLeeJ-HSeenD-Set al. One-step sequence- and ligation-independent cloning as a rapid and versatile cloning method for functional genomics studies. Appl Environ Microbiol. (2012) 78:5440–3. doi: 10.1128/AEM.00844-12

  • 25

    DoganIBertocciBVilmontVDelbosFMégretJStorckSet al. Multiple layers of B cell memory with different effector functions. Nat Immunol. (2009) 10:1292–9. doi: 10.1038/ni.1814

  • 26

    KennedyDEOkoreehMKMaienschein-ClineMAiJVeselitsMMcLeanKCet al. Novel specialized cell state and spatial compartments within the germinal center. Nat Immunol. (2020) 21(6):660–70. doi: 10.1038/s41590-020-0660-2

  • 27

    PikorNBMörbeULütgeMGil-CruzCPerez-ShibayamaCNovkovicMet al. Remodeling of light and dark zone follicular dendritic cells governs germinal center responses. Nat Immunol. (2020) 21(6):649–59. doi: 10.1038/s41590-020-0672-y

  • 28

    NakagawaRToboso-NavasaASchipsMYoungGBhaw-RosunLLlorian-SopenaMet al. Permissive selection followed by affinity-based proliferation of GC light zone B cells dictates cell fate and ensures clonal breadth. PNAS. (2021) 118(2):e2016425118. doi: 10.1073/pnas.2016425118

  • 29

    ShinnakasuRInoueTKometaniKMoriyamaSAdachiYNakayamaMet al. Regulated selection of germinal-center cells into the memory B cell compartment. Nat Immunol. (2016) 17:861–9. doi: 10.1038/ni.3460

  • 30

    Hagemann-JensenMZiegenhainCChenPRamsköldDHendriksG-JLarssonAJMet al. Single-cell RNA counting at allele and isoform resolution using Smart-seq3. Nat Biotechnol. (2020) 38:708–14. doi: 10.1038/s41587-020-0497-0

  • 31

    HoIYBunkerJJEricksonSANeuKEHuangMCorteseMet al. Refined protocol for generating monoclonal antibodies from single human and murine B cells. J Immunol Methods. (2016) 438:6770. doi: 10.1016/j.jim.2016.09.001

  • 32

    HahautVPavlinicDCarboneWSchuiererSBalmerPQuinodozMet al. Fast and highly sensitive full-length single-cell RNA sequencing using FLASH-seq. Nat Biotechnol. (2022) 40(10):1447–51. doi: 10.1038/s41587-022-01312-3

  • 33

    GieselmannLKreerCErcanogluMSLehnenNZehnerMSchommersPet al. Effective high-throughput isolation of fully human antibodies targeting infectious pathogens. Nat Protoc. (2021) 16:3639–71. doi: 10.1038/s41596-021-00554-w

  • 34

    HanXWangYLiSHuCLiTGuCet al. A rapid and efficient screening system for neutralizing antibodies and its application for SARS-cov-2. Front Immunol. (2021) 12:653189. doi: 10.3389/fimmu.2021.653189

Summary

Keywords

B cells, single-cell RNA-seq, antibody cloning, BCR sequencing, antigen specificity

Citation

Ado S, Dong C, Attaf N, Moussa M, Carrier A, Milpied P and Navarro J-M (2024) FB5P-seq-mAbs: monoclonal antibody production from FB5P-seq libraries for integrative single-cell analysis of B cells. Front. Immunol. 15:1505971. doi: 10.3389/fimmu.2024.1505971

Received

04 October 2024

Accepted

26 November 2024

Published

17 December 2024

Volume

15 - 2024

Edited by

Christopher Sundling, Karolinska Institutet (KI), Sweden

Reviewed by

Joanne Reed, Westmead Institute for Medical Research, Australia

Monika Adori, Karolinska Institutet (KI), Sweden

Updates

Copyright

*Correspondence: Pierre Milpied, ; Jean-Marc Navarro,

†These authors share first authorship

‡These authors share senior authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics